← Back to Search

CAR T-cell Therapy

Cohort 4 for Leukemia

Phase 1 & 2
Waitlist Available
Led By John A Lust, MD, PhD
Research Sponsored by Senesco Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up weeks 3 and 6, and monthly during a 24-week follow-up period
Awards & highlights

Study Summary

The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses.

Eligible Conditions
  • Leukemia
  • Multiple Myeloma
  • Mantle Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • B-Cell Lymphoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~weeks 3 and 6, and monthly during a 24-week follow-up period
This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 3 and 6, and monthly during a 24-week follow-up period for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and tolerability
Secondary outcome measures
Explore tumor response
Profile of pharmacokinetics

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment1 Intervention
0.375 mg/kg
Group II: Cohort 3Experimental Treatment1 Intervention
0.2 mg/kg
Group III: Cohort 2Experimental Treatment1 Intervention
0.05 mg/kg
Group IV: Cohort 1Experimental Treatment1 Intervention
0.0125 mg/kg

Find a Location

Who is running the clinical trial?

Senesco Technologies, Inc.Lead Sponsor
John A Lust, MD, PhDPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
2011. "Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01435720.
All > Plasma Cell Leukemia > Myeloma
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top